ENGLEWOOD CLIFFS, N.J.--(BUSINESS WIRE)--Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced that the results of a study investigating the therapeutic effect of oral and parenteral administration of anti-eotaxin-1 antibodies in an animal model of immune-mediated hepatitis will be presented at The Liver Meeting 2017 – the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place October 20-24, 2017 in Washington, DC. Dr. Yaron Ilan, Professor of Medicine, and Director, Department of Medicine at Hebrew University's Hadassah Hospital in Jerusalem, Israel, and an Immune Pharmaceuticals collaborator, will present the data in a poster.
The poster (#350), entitled “Oral administration of anti-eotaxin-1 monoclonal antibody is biologically active in the gut and alleviates immune-mediated hepatitis: A novel personalized therapy for immune-associated liver diseases” (#350) will be presented Friday, October 20 between 12:00 and 1:30 PM ET at the “Autoimmune and Cholestatic Liver Disease” session. The study aimed to evaluate the biological activity and immunomodulatory effect of oral and parenteral administration of anti-eotaxin-1 antibodies in the concanavalin A (ConA) mouse model of immune hepatitis. Anti-eotaxin-1 antibodies, administered two hours prior to the induction of hepatitis, lowered eotaxin-1 levels and prevented the development of hepatitis compared to controls.
Dr. Ilan commented, “These experiments showed that blocking eotaxin-1 can have a profound impact on the development of hepatic inflammation. Anti-eotaxin-1 antibodies lowered eotaxin-1 levels and were effective at blocking liver injury whether administered parenterally or orally. These results have obvious implications for the potential use of bertilimumab in liver diseases in which chronic inflammation plays a role, including NASH.”
Elliot Maza, President and Chief Executive Officer of Immune Pharmaceuticals, stated, “Our collaboration with Dr. Ilan has been fruitful and yielded results suggesting that blocking eotaxin-1 can have a beneficial effect in liver diseases. We will continue to explore the development of bertilimumab in liver diseases, further to our strategic business plan of focusing our resources on this first-in-class antibody.”
About Immune Pharmaceuticals
Immune Pharmaceuticals is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Our lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, we are conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other diseases, including NASH, atopic dermatitis, immune and inflammatory hepatitis, and asthma.
Safe Harbor Statements Regarding Forward Looking Statements
The statements in this news release made by representatives of Immune Pharmaceuticals, Inc. relating to matters that are not historical facts, including without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Immune's product candidates and the sufficiency of Immune's cash and other capital resources, the continued development by Immune of bertilimumab or its determination to seek Orphan Drug designation for the pharmaceutical product of bertilimumab are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Immune's ability to fund such efforts with or without partners. Immune undertakes no obligation to update any of these statements. In addition, there can be no assurance that the Company will ever successfully complete its anticipated corporate restructuring, or that the Company will be able to reduce expenses, capitalize on strategic alternatives, develop its assets, and generate value for shareholders. The Company may, at any time and for any reason until the proposed spin-off is complete, abandon the spin-off or modify its terms and conditions, or consider competing, alternate or complimentary transactions or offers by third parties at the discretion of Immune’s board of directors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Immune's filings with the Securities and Exchange Commission, including those discussed in Immune's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q periodic reports filed on Form 8-K.